Immunohistochemical CCR4 expression is 14–97% in the skin of CTCL patients and 90–100% in the clinical trials enrolling patients with relapsed diseases. This evidence concerns the gene CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma.